Subcutaneous Daratumumab Approved in Europe for Myeloma
The European Commission has approved subcutaneous formulation of daratumumab for the treatment of patients with multiple myeloma.
Related Articles
Retrospective Study Highlights Evolving Community Use of BTK Inhibitors for CLL/SLL
A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.
First-Line Rucaparib Maintenance Provides Long-Term Benefits in Newly Diagnosed Ovarian Cancer
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.
The Critical Nature of Decision-Making in the Development of Phase 3 Clinical Trials
Randomized trials are widely recognized to play a pivotal role in the decision-making associated with the establishment of clinical guidelines.
Current Treatment Options in Third-line MCL
Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study
Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small…
Avutometinib Plus Defactinib Makes a Phase 3 Debut in Low-Grade Serous Ovarian Cancer
Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.
Revisit Every OncLive On Air Episode from March 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.
Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers
The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.
Study Provides a First Look at Oncologists’ Views on Ethical Implications of AI in Cancer Care
In a survey, over 200 oncologists agreed on how AI can be responsibly integrated into patient care and how to protect patients from hidden biases…
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.